Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Results of Annual General Meeting

Thursday, November 16, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced significant developments, including the dosing of the first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These updates highlight the company's ongoing commitment to advancing its clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics is actively progressing with clinical studies.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Announcements
• November 16, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• February 23, 2024
• Announcements
• September 20, 2022
• Announcements
• May 29, 2023
• Updates
• January 24, 2025

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent clinical study did Radiopharm Theranostics initiate?

Radiopharm Theranostics initiated a Phase 1/2a clinical study of BetaBart (RV-01).

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to start a therapeutic clinical study targeting B7H3.

What updates were provided by Radiopharm Theranostics?

Radiopharm provided positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart clinical study FDA approval radiopharmaceuticals
Last updated: Nov 16, 2023